Exercise of Share Options

RNS Number : 9059G

Alliance Pharma PLC

12 June 2013

 



For immediate release

12 June 2013

 

ALLIANCE PHARMA PLC

("Alliance" or the "Company")

Exercise of Share Options

Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, announces that following the exercise of employee share options on 12 June 2013, application has been made by Alliance for a further 205,985 ordinary shares of 1 pence each in the Company ("Ordinary Shares") to be admitted to trading on AIM.

It is expected that these new Ordinary Shares, which will rank pari passu in all respects with the existing Ordinary Shares, will be admitted to trading on 18 June 2013.

Following the admission of the 205,985 Ordinary Shares, Alliance will have 250,023,628 Ordinary Shares in issue.  

For further information:

Alliance Pharma plc	+ 44 (0) 1249 466966
John Dawson, Chief Executive Officer
Richard Wright, Finance Director
Buchanan	+ 44 (0) 20 7466 5000
Mark Court / Fiona Henson / Sophie Cowles www.buchanan.uk.com
Numis Securities Limited	+ 44 (0) 20 7260 1000
Nominated Adviser: Michael Meade / Oliver Cardigan
Corporate Broking: David Poutney

Notes to editors:

About Alliance

Alliance, founded in 1998, is an AIM listed speciality pharmaceutical company based in Chippenham, Wiltshire, UK. The Company has a strong track record of acquiring the rights to established niche products and owns or licenses the rights to more than 50 pharmaceutical products and continues to explore opportunities to expand the range.

Alliance's products are prescribed in the treatment of a wide range of conditions and include products used in the treatment of dermatological conditions, in oncology, in the prevention of heart disease, in Parkinson's disease, in nutrition and in nasal infections.  Alliance's sales are mainly prescription driven.  Its products are distributed to hospitals directly and to pharmaceutical wholesalers, which service both hospital and retail pharmacies with their prescription requirements.

Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.

 

END

 

 

MSCLLFEVRIIFLIV